Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes

Abraham, 2009, A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine, Clin. Cancer Res., 15, 3574, 10.1158/1078-0432.CCR-08-0938 Aller, 2009, Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding, Science, 323, 1718, 10.1126/science.1168750 Breedveld, 2005, Cancer Res., 65, 2577, 10.1158/0008-5472.CAN-04-2416 Chearwae, 2004, Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder, Biochem. Pharmacol., 68, 2043, 10.1016/j.bcp.2004.07.009 Cordon-Cardo, 1990, Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues, J. Histochem. Cytochem., 38, 1277, 10.1177/38.9.1974900 Davies, 2009, Nilotinib concentration in cell lines and primary CD34+chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters, Leukemia, 23, 1999, 10.1038/leu.2009.166 Eswar, 2006, Comparative protein structure modeling using MODELLER, Curr. Protoc. Bioinform., 10.1002/0471250953.bi0506s15 Glavinas, 2004, The role of ABC transporters in drug resistance, metabolism and toxicity, Curr. Drug Deliv., 1, 27, 10.2174/1567201043480036 Gottesman, 2002, Multidrug resistance in cancer: role of ATP-dependent transporters, Nat. Rev. Cancer, 2, 48, 10.1038/nrc706 Haimeur, 2004, The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation, Curr. Drug Metab., 5, 21, 10.2174/1389200043489199 Hu, 2008, Tenacigenin B derivatives reverse P-glycoprotein-mediated multidrug resistance inHepG2/Dox cells, J. Nat. Prod., 71, 1049, 10.1021/np070458f Huang, 2013, Effect of Xiaoaiping injection on advanced hepatocellular carcinoma in patients, J. Tradit. Chin. Med., 33, 34, 10.1016/S0254-6272(13)60097-7 Humphrey, 1996, VMD: visual molecular dynamics, J. Mol. Graph., 14, 27, 10.1016/0263-7855(96)00018-5 Jain, 2007, Reversal of P-glycoprotein-mediated multidrug resistance by sipholane triterpenoids, J. Nat. Prod., 70, 928, 10.1021/np0605889 Janneh, 2005, Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP, Aids, 19, 2097, 10.1097/01.aids.0000194793.36175.40 Kadioglu, 2016, Interactions of human P-glycoprotein transport substrates and inhibitors at the drug binding domain: functional and molecular docking analyses, Biochem. Pharmacol., 104, 42, 10.1016/j.bcp.2016.01.014 Kruijtzer, 2002, Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918, J. Clin. Oncol., 20, 2943, 10.1200/JCO.2002.12.116 Lai, 1991, P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines, Inter. J. Cancer, 49, 696, 10.1002/ijc.2910490512 Leonard, 2002, ABC transporters and inhibitors: new targets, new agents, Curr. Opin. Invest. Drugs, 3, 1652 Leonard, 2003, The role of ABC transporters in clinical practice, Oncologist, 8, 411, 10.1634/theoncologist.8-5-411 Leslie, 2003, Structural requirements for functional interaction of glutathione tripeptide analogs with the human multidrug resistance protein 1 (MRP1), J. Pharmacol. Exp. Ther., 304, 643, 10.1124/jpet.102.044073 Li, 2014, Refined structures of mouse P-glycoprotein, Protein Sci., 23, 34, 10.1002/pro.2387 Litman, 2000, The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2), J. Cell Sci., 113, 2011, 10.1242/jcs.113.11.2011 Minderman, 2004, VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein, Clin. Cancer Res., 10, 1826, 10.1158/1078-0432.CCR-0914-3 Newman, 2007, Natural products as sources of new drugs over the last 25 years, J. Nat. Prod., 70, 461, 10.1021/np068054v Pusztai, 2005, Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma, Cancer, 104, 682, 10.1002/cncr.21227 Robey, 2007, ABCG2: determining its relevance in clinical drug resistance, Cancer Metast. Rev., 26, 39, 10.1007/s10555-007-9042-6 Robey, 2001, Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells, Clin. Cancer Res., 7, 145 Schneider, 1994, Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance, Cancer Res., 54, 152 Seelig, 1998, A general pattern for substrate recognition by P‐glycoprotein, Eur. J. Biochem., 251, 252, 10.1046/j.1432-1327.1998.2510252.x Si-Qi, 1993, Polyoxypregnanes from Marsdenia tenacissima, Phytochemistry, 34, 1615, 10.1016/S0031-9422(00)90856-2 Skehan, 1990, New colorimetric cytotoxicity assay for anticancer-drug screening, J. Natl. Cancer Inst., 82, 1107, 10.1093/jnci/82.13.1107 Staud, 2005, Breast cancer resistance protein (BCRP/ABCG2), Int. J. Biochem. Cell Biol., 37, 720, 10.1016/j.biocel.2004.11.004 Stewart, 2004, Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice, Cancer Res., 64, 7491, 10.1158/0008-5472.CAN-04-0096 Szakács, 2006, Targeting multidrug resistance in cancer, Nat. Rev. Drug Discov., 5, 219, 10.1038/nrd1984 Thiebaut, 1987, Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues, Proc. Nat. Acad. Sci. USA, 84, 7735, 10.1073/pnas.84.21.7735 To, 2011, Upregulation of ABCG2 by romidepsin via the aryl hydrocarbon receptor pathway, Mol. Cancer Res., 9, 516, 10.1158/1541-7786.MCR-10-0270 Tsuruo, 1981, Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil, Cancer Res., 41, 1967 de Vries, 2007, P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan, Clin. Cancer Res., 13, 6440, 10.1158/1078-0432.CCR-07-1335 Wang, 2004, Reversal of P-glycoprotein-mediated multidrug resistance by Alisol B 23-acetate, Biochem. Pharmacol., 68, 843, 10.1016/j.bcp.2004.05.021 Wang, 2009, A random study of xiaoaiping injection combined with chemotherapy on the treatment of advanced non-small cell lung cancer, Chin. Clin. Oncol., 14, 936 Xueyuan, 1976 Yao, 2014, Polyoxypregnane steroids from the stems of Marsdenia tenacissima, J. Nat. Prod., 77, 2044, 10.1021/np500385b Yao, 2016, Polyoxypregnane steroids with an open-chain sugar moiety from Marsdenia tenacissima and their chemoresistance reversal activity, Phytochemistry, 126, 47, 10.1016/j.phytochem.2016.03.006 Ye, 2014, In vitro and in vivo antitumor activities of tenacissoside C from Marsdenia tenacissima, Planta Med., 80, 29 Ye, Y., Lin, G., Yao, S., To, K., Ma, L., 2013. Polyoxopregnane compounds and use thereof. Patents, China Patent No. WO2013185635 A1. Zhuang, 2006, Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor, Cancer Res., 66, 11305, 10.1158/0008-5472.CAN-06-0929